Theratechnologies Inc., a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. The company's lead product is EGRIFTA, which increases the incidence or progression of diabetic retinopathy in diabetic HIV-infected patients with lipodystrophy and excess abdominal fat in the United States and Canada. Theratechnologies Inc. was founded in 1993 and is headquartered in Montreal, Canada.
Industry, Sector and Symbol
Stock Exchange TSE
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolTSE:TH
Previous Symbol
CUSIPN/A
Phone+1-514-3367800
Debt
Debt-to-Equity Ratio137.57
Current Ratio2.89
Quick Ratio2.40
Price-To-Earnings
Trailing P/E Ratio-71.19
Forward P/E Ratio18.64
P/E Growth-955.68
Sales & Book Value
Annual SalesC$52.85 million
Price / Sales12.18
Cash FlowC$0.77 per share
Price / Cash Flow10.93
Book ValueC$0.61 per share
Price / Book13.88
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees28
Outstanding Shares76,659,000
Market CapC$0.00
OptionableNot Optionable
Theratechnologies (TSE:TH) Frequently Asked Questions
What is Theratechnologies' stock symbol?
Theratechnologies trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TH."
How were Theratechnologies' earnings last quarter?
Theratechnologies Inc (TSE:TH) posted its quarterly earnings results on Thursday, October, 4th. The company reported $0.02 earnings per share (EPS) for the quarter. The business earned $17.71 million during the quarter, compared to the consensus estimate of $17.17 million. View Theratechnologies' Earnings History.
When is Theratechnologies' next earnings date?
What price target have analysts set for TH?
2 analysts have issued 12-month target prices for Theratechnologies' shares. Their forecasts range from C$12.00 to C$15.00. On average, they expect Theratechnologies' stock price to reach C$13.94 in the next twelve months. This suggests a possible upside of 65.9% from the stock's current price. View Analyst Price Targets for Theratechnologies.
What is the consensus analysts' recommendation for Theratechnologies?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Theratechnologies.
Has Theratechnologies been receiving favorable news coverage?
Media stories about TH stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Theratechnologies earned a news impact score of -1.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
Who are some of Theratechnologies' key competitors?
Some companies that are related to Theratechnologies include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB) and Antibe Therapeutics (ATE).
Who are Theratechnologies' key executives?
Theratechnologies' management team includes the folowing people:
- Mr. Luc Tanguay, Pres, CEO & Non-Independent Director (Age 60)
- Mr. Philippe Dubuc, Sr. VP & CFO (Age 51)
- Mr. Jocelyn Lafond, VP of Legal Affairs & Corp. Sec. (Age 50)
- Mr. Christian Marsolais, Sr. VP & Chief Medical Officer (Age 55)
- Ms. Lyne Fortin, Sr. VP & Chief Commercial Officer (Age 58)
How do I buy shares of Theratechnologies?
Shares of TH and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Theratechnologies' stock price today?
One share of TH stock can currently be purchased for approximately C$8.40.
What is Theratechnologies' official website?
How can I contact Theratechnologies?
Theratechnologies' mailing address is 2015 Peel St 5th Floor, MONTREAL, QC H3A 1T8, Canada. The company can be reached via phone at +1-514-3367800.
MarketBeat Community Rating for Theratechnologies (TSE TH)
MarketBeat's community ratings are surveys of what our community members think about Theratechnologies and other stocks. Vote "Outperform" if you believe TH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TH will underperform the S&P 500 over the long term. You may vote once every thirty days.
